A Riddle Wrapped in a Mystery inside an Enigma, Clin Cancer Res, vol.23, issue.7, pp.1629-1637, 2017. ,
Anatomy of the pancreas and spleen, Surgery (Oxford), vol.37, issue.6, pp.297-301, 2019. ,
, Terese Winslow LLC Medical Illustration, pour le National Cancer Institute, 2009.
Pancreatic cancer biology and genetics, Nat Rev Cancer, vol.2, issue.12, pp.897-909, 2002. ,
The Exocrine Pancreas, Morgan & Claypool Life Sciences; 2010. Digestive Enzymes ,
Anatomy and Histology of the Pancreas. Pancreapedia: Exocrine Pancreas Knowledge Base, 2014. ,
A Historical Perspective on the Identification of Cell Types in Pancreatic Islets of Langerhans by Staining and Histochemical Techniques, J Histochem Cytochem, vol.63, issue.8, pp.543-558, 2015. ,
, American Gastroenterological Association. Cross section of the upper abdomen at the level of the pancreas
, International Classification of Diseases for Oncology, Institut National du Cancer. Classification des cancers Disponible
Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-674, 2011. ,
, Cancers et tumeurs du pancréas, 2019.
, National Cancer Institute, Pancreas Stats, 2013.
Épidémiologie du cancer du pancréas, Bulletin du Cancer, vol.105, issue.1, pp.63-69, 2018. ,
Young Patients Undergoing Resection of Pancreatic Cancer Fare Better than their Older Counterparts, J Gastrointest Surg, vol.17, issue.2, pp.339-344, 2013. ,
Inherited Pancreatic Cancer Syndromes, Cancer J, vol.18, issue.6, pp.485-491, 2012. ,
Importance of age of onset in pancreatic cancer kindreds, JNCI, vol.102, pp.119-126, 2010. ,
Genetic Susceptibility to Pancreatic Cancer, Mol Carcinog, vol.51, issue.1, pp.14-24, 2012. ,
, Pancreatic cancer Medicine, vol.47, issue.7, pp.433-439, 2019.
Pancreatitis and the Risk of Pancreatic Cancer, NEJM, vol.328, issue.20, pp.1433-1437, 1993. ,
Epidemiology and risk factors for pancreatic cancer, Best Pract Res Clin Gastroenterol, vol.20, issue.2, pp.197-209, 2006. ,
Épidémiologie du cancer du pancréas, Bulletin du Cancer, vol.105, issue.1, pp.63-69, 2018. ,
Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis, Br J Cancer, vol.112, pp.580-93, 2015. ,
Type-II diabetes and pancreatic cancer : A meta-analysis of 36 studies, Br J Cancer, vol.92, pp.2076-83, 2005. ,
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, vol.321, issue.5897, pp.1801-1806, 2008. ,
Pancreatic cancer biology and genetics, Nat Rev Cancer, vol.2, issue.12, pp.897-909, 2002. ,
Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma, Nat Rev Cancer, vol.10, issue.10, pp.683-695, 2010. ,
Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states, Clin Cancer Res, vol.3, issue.6, pp.993-998, 1997. ,
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells, Science, vol.325, issue.5947, pp.1555-1559, 2009. ,
Principles & practice of oncology 11th Edition, 2018. ,
Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer, Nature, vol.467, issue.7319, pp.1114-1117, 2010. ,
Pancreatic cancer biology and genetics, Nat Rev Cancer, vol.2, issue.12, pp.897-909, 2002. ,
Stromal biology and therapy in pancreatic cancer, Gut, vol.60, issue.6, pp.861-868, 2011. ,
Rosenberg Principles & practice of oncology 11th Edition, 2018. ,
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches, Radiat Oncol, vol.14, issue.1, p.141, 2019. ,
Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells, World J Gastroenterol, vol.22, issue.9, pp.2678-2700, 2016. ,
Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy, Cancer research, vol.60, issue.21, pp.6201-6207, 2000. ,
Genetics and biology of pancreatic ductal adenocarcinoma, Genes Dev, vol.20, issue.10, pp.1218-1249, 2006. ,
Tumor microenvironment participates in metastasis of pancreatic cancer, Mol Cancer, vol.17, 2018. ,
Early detection of sporadic pancreatic cancer: summative review, Pancreas, vol.44, issue.5, pp.693-712, 2015. ,
International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer, Gut, vol.62, issue.3, pp.339-347, 2013. ,
, Guide ALD 30 -Cancer du pancreas, 2010.
Systemic treatment of pancreatic cancer revisited, Seminars in Oncology, vol.46, issue.1, pp.28-38, 2019. ,
, Site de l'Union Internationale pour le Control du Cancer (UICC)
, AJCC Cancer Staging Manual, vol.8, pp.337-347, 2017.
Rosenberg Principles & practice of oncology 11th Edition, 2018. ,
Borderline resectableau pancreatic cancer: definitions, management, and role of preoperative therapy, Ann Surg Oncol, vol.13, issue.8, pp.1035-1046, 2006. ,
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Natl Compr Canc Netw, vol.15, pp.1028-1061, 2017. ,
Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: Histopathology, Cytopathology, and Molecular Pathology, Am J Pathol, vol.189, issue.1, pp.9-21, 2019. ,
, Fonds anticancer, guide ESMO pour les patients, vol.56, 2013.
Redefining resection margin status in pancreatic cancer, HPB (Oxford), vol.11, issue.4, pp.282-289, 2009. ,
Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, vol.5, pp.649-655, 1982. ,
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, vol.15, issue.8 ,
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.26, issue.5, pp.56-68, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01810223
,
, Memorial Sloan Kettering Cancer Center
,
Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma, Ann Surg Oncol, vol.25, issue.8, pp.2475-2483, 2018. ,
Institut National du Cancer. Les traitements du cancer du pancréas, collection Guides patients Cancer info, 2012. ,
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol, vol.15, issue.6, pp.2403-2413, 1997. ,
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine, NEJM, vol.369, issue.18, pp.1691-1703, 2013. ,
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer, NEJM, vol.364, issue.19, pp.1817-1825, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00598658
, American Society of Clinical Oncology Educational Book, vol.38, pp.300-305, 2018.
The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis, Cancer Med, vol.5, issue.10, pp.2825-2831, 2016. ,
Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?, J Gastrointest Oncol, vol.5, issue.3, pp.166-177, 2014. ,
Académie de Besancon, 2015. ,
, Banque de schémas SVT Dijon Disponible
L'activation et la prolifération des lymphocytes T CD4+ ,
CD4+ T cell help in cancer immunology and immunotherapy, Nat Rev Immunol, vol.18, pp.635-647, 2018. ,
, Les lymphocytes B et immunité à médiation humorale Disponible à
, Futura Science. Complémentarité Anticorps-antigène Disponible
Oncology meets immunology : the cancer-immunology cycle, Immunity, 2013. ,
Immune infiltration in human tumors: a prognostic factor that should not be ignored, Oncogene, vol.29, issue.8, pp.1093-1102, 2010. ,
, Immunity, inflammation, and cancer. Cell, vol.140, issue.6, pp.883-899, 2010.
Hallmarks of cancer: the next generation, Cell, vol.144, issue.5, pp.646-674, 2011. ,
Chemokine networks and breast cancer metastasis, Breast Dis, vol.26, pp.75-85, 2006. ,
Macrophage diversity enhances tumor progression and metastasis, Cell, vol.141, issue.1, pp.39-51, 2010. ,
Accessories to the crime: functions of cells recruited to the tumor microenvironment, Cancer Cell, vol.21, issue.3, pp.309-322, 2012. ,
Chronic inflammation in cancer development, Front Immunol, vol.2, p.98, 2012. ,
Advances in cancer immunotherapy 2019 -latest trends, J Exp Clin Cancer Res, vol.38, 2019. ,
A Nobel prize-worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens, Immunology, vol.155, issue.3, pp.283-287, 2018. ,
Genetic cancer vaccines: current status and perspectives, Expert Opin Biol Th, vol.12, pp.1043-1058, 2012. ,
, Cancer Research Institute. Cancer Vaccines. Disponible à www.cancerresearch.org
The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, vol.12, issue.4, pp.252-264, 2012. ,
Next generation of immune checkpoint therapy in cancer: new developments and challenges, J Hematol Oncol, vol.11, issue.1, p.39, 2018. ,
Immune checkpoint therapy for pancreatic cancer, World J Gastroenterol, vol.22, issue.43, pp.9457-9476, 2016. ,
Management of toxicities of immune checkpoint inhibitors, Cancer Treatment Reviews, vol.44, pp.51-60, 2016. ,
,
Advances in cancer immunotherapy 2019 -latest trends, J Exp Clin Cancer Res, vol.38, 2019. ,
The use of endogenous T cells for adoptive transfer, Immunological Reviews, vol.257, issue.1, pp.250-263, 2014. ,
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells, Biol Blood Marrow Transplant, vol.25, issue.4, pp.625-638, 2019. ,
, National Institute of Health, National Library of Medicine, Clinicaltrial.gov. Disponible à
, Meeting Library
RECIST 1.1-Update and clarification: From the RECIST committee, Eur J Cancer, vol.62, pp.132-137, 2016. ,
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma, J Immunother, vol.33, issue.8, pp.828-833, 2010. ,
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer, J Immunother, vol.36, issue.7, pp.382-389, 2013. ,
Phase Ib study of ipilimumab alone or in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene (vaccine) in pancreatic cancer, 2012. ,
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer, Ann Oncol, vol.25, issue.9, pp.1750-1755, 2014. ,
Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma, JCO, vol.36, issue.4, pp.470-470, 2018. ,
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial, JAMA Oncol, vol.5, issue.10, pp.1431-1438, 2019. ,
Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR), JCO, vol.33, issue.15, pp.4148-4148, 2015. ,
T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma, JCI Insight, vol.3, issue.13, p.122092, 2018. ,
Randomized Phase 2 study of the safety, efficacy and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). ASCO poster ,
Phase I study of nivolumab (Nivo) + nabpaclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC), JCO, vol.37, issue.4, pp.298-298, 2019. ,
Nab-paclitaxel + Nivolumab +/-Gemcitabine in patients with advanced pancreatic cancer, 2016. ,
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus), Br J Cancer, vol.117, issue.1, pp.33-40, 2017. ,
Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers, Annals of Oncology, vol.28, issue.5, pp.122-141, 2017. ,
Phase Ib study of ipilimumab alone or in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene (vaccine) in pancreatic cancer, Aduro Biotech. Engineered Immunotherapy for Cancer, 2012. ,
Novel allogeneic granulocyte-macrophage colonystimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation, J Clin Oncol, vol.19, issue.1, pp.145-156, 2001. ,
A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation, Ann Surg, vol.253, issue.2, pp.328-335, 2011. ,
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients, Cancer Immunol Immunother, vol.56, pp.641-649, 2007. ,
Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation, Cancer Immunol Res, vol.2, issue.7, pp.616-631, 2014. ,
Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer, J Clin Oncol, vol.33, issue.12, pp.1325-1333, 2015. ,
Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation, Cancer Immunol Res, vol.2, issue.7, pp.616-631, 2014. ,
Immunotherapy updates in pancreatic cancer: are we there yet ?, Ther Adv Med Oncol, vol.5, issue.1, pp.81-89, 2013. ,
Correlation of anti-calreticulin antibody titers with improved overall survival in a phase 2 clinical trial of algenpantucel-L immunotherapy for patients with resected pancreatic cancer, 2014. ,
Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study, J Gastrointest Surg, vol.17, issue.1, pp.94-101, 2013. ,
, Results from Phase 3 IMPRESS Trial of Algenpantucel-L for Patients with Resected Pancreatic Cancer Disponible à, 2016.
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma, J Immunother Cancer, vol.1, 2013. ,
Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer, J Clin Oncol, vol.20, issue.20, pp.4225-4231, 2002. ,
An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer, Pancreas, vol.41, issue.3, pp.374-379, 2012. ,
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectableau and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial, Lancet Oncol, vol.17, issue.5, pp.78-82, 2016. ,
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nabpaclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma, Invest New Drugs, pp.1-12, 2019. ,
Phase 2 Trial of the IDO Pathway Inhibitor Indoximod Plus Gemcitabine/Nab-paclitaxel for the Treatment of Patients With Metastatic Pancreas cancer ASCO, 2018. ,
Phase 2 trial of the indoleamine2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of metastatic pancreas cancer:interimanalysisASCO, 2016. ,
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma, Clin Cancer Res, vol.19, issue.22, pp.6286-6295, 2013. ,
The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. Tumori, vol.104, pp.88-95, 2018. ,
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol, vol.20, issue.5, pp.30074-30082, 2017. ,
, New Drug Approval for Pembrolizumab
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?, World J Gastroenterol, vol.24, issue.20, pp.2137-2151, 2018. ,
Signatures of mutational processes in human cancer, 258. Imielinsk, Marcin, vol.502, pp.415-421, 2013. ,
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, vol.357, issue.6349, pp.409-413, 2017. ,
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy, Nature, vol.551, issue.7681, pp.517-520, 2017. ,
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer, Nature, vol.551, issue.7681, pp.512-516, 2017. ,
Selective changes in expression of HLA class I polymorphic determinants in human solid tumors, Proc Natl Acad Sci U S A, vol.86, issue.17, pp.6719-6723, 1989. ,
Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer, Br J Cancer, vol.113, pp.1343-1349, 2015. ,
Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma, Clin Cancer Res, vol.11, issue.2, pp.498-504, 2005. ,
Cold Tumors: A Therapeutic Challenge for, Immunotherapy. Front Immunol, vol.10, p.168, 2019. ,
Paucity of dendritic cells in pancreatic cancer, Surgery, vol.131, issue.2, pp.135-138, 2002. ,
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition, Clin Cancer Res, pp.1865-1874, 2016. ,
Cold Tumors: A Therapeutic Challenge for, Immunotherapy. Front Immunol, vol.10, p.168, 2019. ,
Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment, Front Immunol, vol.9, p.1044, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02143543
Systemic treatment of pancreatic cancer revisited, Seminars in Oncology, vol.46, issue.1, pp.28-38, 2019. ,
Stromal biology and therapy in pancreatic cancer: ready for clinical translation?, Gut, vol.68, issue.1, pp.159-171, 2019. ,
Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer, Oncogene, vol.36, pp.439-445, 2017. ,
Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle, J Gastrointest Oncol, vol.9, issue.6, pp.1014-1026, 2018. ,
CD40 combination therapy can shrink pancreatic tumors Disponible à ,